Skip to main content
SpringerLink
Log in

Surgical Management of Uterine Sarcoma

  • Chapter
Book cover Uterine Cancer

  • 1173 Accesses

Abstract

Uterine sarcomas are rare malignant tumors of mesenchymal origin and account for 3–8 % of all uterine cancers [1, 2]. They are heterogeneous tumors of diverse histological types. The three most common subtypes are carcinosarcoma (CS) also known as malignant mixed Mullerian tumor (MMMT), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS). Although recently carcinosarcoma has been reclassified as a dedifferentiated or metaplastic form of endometrial carcinoma [3], it is still included in most studies on uterine sarcomas. The important pure mesenchymal malignant tumors of the uterus are leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS). Uterine sarcomas are in general the most malignant group of uterine tumors and differ from endometrial cancers with respect to diagnosis, clinical behavior, pattern of spread, and management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zaloudek C, Hendrickson M. Mesenchymal tumors of the uterus. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer; 2002. p. 561–615.

    Google Scholar 

  2. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93:204–8.

    Article  PubMed  Google Scholar 

  3. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505.

    Article  PubMed  Google Scholar 

  4. El Husseiny G, Al Bareedy N, Mourad WA, et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol. 2002;25:256–60.

    Article  PubMed  Google Scholar 

  5. Kapp D, Shin J, Chan J. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. Emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820–30.

    Article  PubMed  Google Scholar 

  6. Bokhman JV, Yakovleva IA, Urmanchejeva AF. Treatment of patients with sarcoma of the uterus. Eur J Gynaecol Oncol. 1990;11:225–31.

    CAS  PubMed  Google Scholar 

  7. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl):702–9.

    Google Scholar 

  8. Gard GB, Mulvany NJ, Quinn MA. Management of uterine leiomyosarcoma in Australia. Aust N Z J Obstet Gynaecol. 1999;39:93–8.

    CAS  PubMed  Google Scholar 

  9. Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003;91:209–12.

    Article  PubMed  Google Scholar 

  10. Larson B, Silfversward C, Nilsson B, et al. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936–1981. Acta Oncol. 1990;29:185–91.

    Article  CAS  PubMed  Google Scholar 

  11. Giuntoli 2nd RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460–9.

    Article  PubMed  Google Scholar 

  12. Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;62:25–32.

    Article  CAS  PubMed  Google Scholar 

  13. Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006;100:166–72.

    Article  PubMed  Google Scholar 

  14. Garg G, Shah JP, Liu JR, Bryant CS, Kumar S, Munkarah A. Morris RT validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study. Int J Gynecol Cancer. 2010;20(7):1201–6.

    Article  PubMed  Google Scholar 

  15. Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller Jr AF. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993;50(1):105–9.

    Article  CAS  PubMed  Google Scholar 

  16. Ayhan A, Tuncer ZS, Tanir M, et al. Uterine sarcoma: the Hacettepe hospital experience of 88 consecutive patients. Eur J Gynaecol Oncol. 1997;18:146–8.

    CAS  PubMed  Google Scholar 

  17. Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol. 2008;134:1277–87.

    Article  PubMed  Google Scholar 

  18. Koivisto-Korander R, Butzow R, Koivisto AM, et al. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol. 2008;111:74–81.

    Article  PubMed  Google Scholar 

  19. Hoellen F, Waldmann A, Benthin S, Hanker L, Rody A, Fischer D. The role of lymphadenectomy in uterine sarcoma: a clinical practical approach based on retrospective analysis. Anticancer Res. 2014;34(2):985–93.

    PubMed  Google Scholar 

  20. Leitao Jr MM, Zivanovic O, Chi DS, Hensley ML, O’Cearbhaill R, Soslow RA, Barakat RR. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125(2):409–13.

    Article  PubMed  Google Scholar 

  21. Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol. 1992;45:202–5.

    Article  CAS  PubMed  Google Scholar 

  22. Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287–94.

    Article  PubMed  Google Scholar 

  23. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355–64.

    Article  PubMed  Google Scholar 

  24. Chan JK, Kawar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99:1210–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Hendrickson MR, Tavassoli FA, Kempson RL, et al. Mesenchymal tumours and related lesions. In: Tavassoli FA, Deville P, editors. Pathology and genetics of tumours of the breast and female organs. Lyon: IARC Press; 2003. p. 233–44.

    Google Scholar 

  26. Xue WC, Cheung AN. Endometrial stromal sarcoma of uterus. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):719–32.

    Article  PubMed  Google Scholar 

  27. Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido. Jpn Oncol. 2004;67:33–9.

    Article  Google Scholar 

  28. Dos Santos LA, Garg K, Diaz JP, et al. Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol. 2011;121:319–22.

    Article  PubMed  Google Scholar 

  29. Li N, Wu LY, Zhang HT, et al. Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol. 2008;108:306–11.

    Article  PubMed  Google Scholar 

  30. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial stromal tumors. Gynecol Oncol. 1990;36:60–5.

    Article  CAS  PubMed  Google Scholar 

  31. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170–6.

    Article  CAS  PubMed  Google Scholar 

  32. Li AJ, Giuntoli 2nd RL, Drake R, et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005;106:1304–8.

    Article  PubMed  Google Scholar 

  33. Amant F, De Knijf A, Van Calster B, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007;97:1194–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Shah JP, Bryant CS, Kumar S, et al. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112:1102–8.

    Article  PubMed  Google Scholar 

  35. Kim WY, Lee JW, Choi CH, et al. Low-grade endometrial stromal sarcoma: a single center’s experience with 22 cases. Int J Gynecol Cancer. 2008;18:1084–9.

    Article  CAS  PubMed  Google Scholar 

  36. Bai H, Yang J, Cao D, Huang H, Xiang Y, Wu M, Cui Q, Chen J, Lang J, Shen K. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol. 2014;132(3):654–60.

    Article  PubMed  Google Scholar 

  37. Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW, Nam JH. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;132(1):70–5.

    Article  PubMed  Google Scholar 

  38. Feng W, Hua K, Malpica A, Zhou X, Baak JP. Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough? Int J Gynecol Cancer. 2013;23(3):488–93.

    Article  PubMed  Google Scholar 

  39. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;63(2):247–53.

    Article  CAS  PubMed  Google Scholar 

  40. Riopel J, Plante M, Renaud MC, et al. Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol. 2005;96:402–6.

    Article  CAS  PubMed  Google Scholar 

  41. Reich O, Winter R, Regauer S. Should lymphadenectomy be performed in patients with endometrial stromal sarcoma? Gynecol Oncol. 2005;97:982.

    Article  PubMed  Google Scholar 

  42. Leath 3rd CA, Huh WK, Hyde Jr J, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105:630–4.

    Article  PubMed  Google Scholar 

  43. Signorelli M, Fruscio R, Dell’Anna T, et al. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. Int J Gynecol Cancer. 2010;20:1363–6.

    PubMed  Google Scholar 

  44. Dong R, Pang Y, Mao H, Yang N, Liu P. Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: a case report. Oncol Lett. 2014;7(4):1039–42.

    PubMed Central  PubMed  Google Scholar 

  45. Yan L, Tian Y, Fu Y, Zhao X. Successful pregnancy after fertility-preserving surgery for endometrial stromal sarcoma. Fertil Steril. 2010;93:269.e1–3.

    Google Scholar 

  46. Delaney AA, Gubbels AL, Remmenga S, Tomich P, Molpus K. Successful pregnancy after fertility-sparing local resection and uterine reconstruction for low-grade endometrial stromal sarcoma. Obstet Gynecol. 2012;120:486–9.

    Article  PubMed  Google Scholar 

  47. Koskas M, Morice P, Yazbeck C, Duvillard P, Walker F, Madelenat P. Conservative management of low-grade endometrial stromal sarcoma followed by pregnancy and severe recurrence. Anticancer Res. 2009;29:4147–50.

    PubMed  Google Scholar 

  48. Morimoto A, Tsubamoto H, Inoue K, Ikeda Y, Hirota S. Fatal case of multiple recurrences of endometrial stromal sarcoma after fertility-sparing management. J Obstet Gynaecol Res. 27 Aug 2014. doi:10.1111/jog.12506. [Epub ahead of print].

    Google Scholar 

  49. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10:1188–98.

    Article  PubMed  Google Scholar 

  50. Takamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest. 1999;48:193–6.

    Article  CAS  PubMed  Google Scholar 

  51. Leibsohn S, d’Ablaing G, Mishell Jr DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968–74.

    Article  CAS  PubMed  Google Scholar 

  52. FDA safety communication: laparoscopic uterine morcellation in hysterectomy and myomectomy. 2014. www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576

  53. Rekha W, Amita M, Sudeep G, Hemant T. Unexpected complication of uterine myoma morcellation. Aust N Z J Obstet Gynaecol. 2005;45(3):248–9.

    Article  PubMed  Google Scholar 

  54. Morice P, Rodriguez A, Rey A, et al. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol. 2003;24:237–40.

    CAS  PubMed  Google Scholar 

  55. Park JY, Park SK, Kim DY, et al. The impact of tumor Morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122:255–9.

    Article  PubMed  Google Scholar 

  56. Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer. 2009;19:257–60.

    Article  PubMed  Google Scholar 

  57. George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014. doi:10.1002/cncr.28844.

    Google Scholar 

  58. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms [serial online]. PLoS One. 2012;7:e50058.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer. 2008;18:1065–70.

    Article  CAS  PubMed  Google Scholar 

  60. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18(12):3453–61.

    Article  PubMed  Google Scholar 

  61. Oduyebo T, Rauh-Hain AJ, Meserve EE, Seidman MA, Hinchcliff E, George S, Quade B, Nucci MR, Del Carmen MG, Muto MG. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014;132(2):360–5.

    Article  PubMed  Google Scholar 

  62. Galaal K, Kew FM, Tam KF, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol. 2009;143:88–92.

    Article  CAS  PubMed  Google Scholar 

  63. Inthasorn P, Carter J, Valmadre S. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer. 2002;12:348–53.

    Article  CAS  PubMed  Google Scholar 

  64. Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997;67:70–5.

    Article  CAS  PubMed  Google Scholar 

  65. Kokawa K, Nishiyama K, Ikeuchi M, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990–2003). Int J Gynecol Cancer. 2006;16:1358–63.

    Article  CAS  PubMed  Google Scholar 

  66. Yamada SD, Burger RA, Brewster WR, et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782–6.

    Article  CAS  PubMed  Google Scholar 

  67. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58:786–96.

    Article  PubMed  Google Scholar 

  68. Nemani D, Mitra N, Guo M, et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82–8.

    Article  PubMed  Google Scholar 

  69. Park JY, Kim DY, Kim JH, et al. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol. 2010;17:861–8.

    Article  PubMed  Google Scholar 

  70. Garg G, Kruger M, Christensen C, Deppe G, Toy EP. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics staging system and prognostic determinants. Int J Gynecol Cancer. 2011;21(9):1606–12.

    Article  PubMed  Google Scholar 

  71. Geszler G, Szpak CA, et al. Prognostic value of peritoneal washings in patients with malignant mixed mullerian tumors of the uterus. Am J Obstet Gynecol. 1986;155:83–9.

    Article  CAS  PubMed  Google Scholar 

  72. Barakat RR, Markman M, Randall M. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott, Williams & Wilkins; 2009.

    Google Scholar 

  73. Giuntoli 2nd RL, Garrett-Mayer E, Bristow RE, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–8.

    Article  PubMed  Google Scholar 

  74. Korets SB, Curtin JP. Surgical options for recurrent uterine sarcomas. Am Soc Clin Oncol Educ Book. 2012:362–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynecologic Oncology, Tata Memorial Hospital, Mumbai, India

    Amita Maheshwari (Professor)

Authors
  1. Amita Maheshwari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amita Maheshwari .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, University College of Medical Sciences, New Delhi, India

    Shalini Rajaram

  2. Surgical &Gynec Oncology, Lakeshore & Welcare Hospitals, Kochi, Kerala, India

    Chitrathara K

  3. Gynec Onclogy, Tata Memorial Hospital, Mumbai, India

    Amita Maheshwari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer India

About this chapter

Cite this chapter

Maheshwari, A. (2015). Surgical Management of Uterine Sarcoma. In: Rajaram, S., K, C., Maheshwari, A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_31

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1892-0_31

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1891-3

  • Online ISBN: 978-81-322-1892-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation